Evaluation of a biosimilar recombinant alpha epoetin in the management of anemia in hemodialysis patients

详细信息    查看全文

• 作者：Fatemeh Beiraghdar^a ; Yunes Panahi^b ; ^{yunespanahi@yahoo.com" class="auth_mail" title="E-mail the corresponding author} ; Behzad Einollahi^a ; Eghlim Nemati^a ; Amirhossein Sahebkar^c ; ^d ; ^{amir_saheb2000@yahoo.com" class="auth_mail" title="E-mail the corresponding author} ; ^{sahebkara@mums.ac.ir" class="auth_mail" title="E-mail the corresponding author} ; Arash Hassanzadeh^a ; Hamid T. Khosroshahi^e ; Sima A. Azar^e ; Javid Safa^e ; Sadroddin R. Hashemi^e ; Jalal Etemadi^e ; Eisa T. Marzony^a ; Hamid Noshad^e
• 关键词：Eprex ; Pastopoitin ; Anemia ; Hemodialysis ; Biosimilar
• 刊名：Journal of the Saudi Pharmaceutical Society
• 出版年：2015
• 出版时间：October 2015
• 年：2015
• 卷：23
• 期：5
• 页码：544-548
• 全文大小：376 K

文摘

Background: The efficacy of human recombinant erythropoietins (rHuEPOs) in the treatment of anemia with different etiologies is proven. Development of biosimilar rHuEPO products with lower cost and wider availability is important for the care of anemic patients. Objective: The aim of the present study was to determine the bioequivalence and safety of a biosimilar rHuEPO (Pastopoitin^®) and compare it with the innovator product Eprex^®, as a standard rHuEPO. Methods: One hundred and seven anemic patients on stable hemodialysis were recruited to this randomized double-blind comparative trial and assigned to either subcutaneous Pastopoitin (n = 50) or Eprex (n = 57). Each study group received rHuEPO at a dose of 80–120 IU/kg/week in 2–3 divided doses for a period of 3 months. Hematologic parameters including Hemoglobin, hematocrit, RBC, EBC, platelet, MCV, MCH and MCHC were checked every 2 weeks. Blood iron, ferritin, TIBC, creatinine, BUN and electrolytes (Na, K, Ca and P) were evaluated monthly over the 3 months. Results: A significant increase in hemoglobin, hematocrit and RBC was observed by the end of study in both Pastopoitin and Eprex groups (p < 0.001). However, these factors were not significantly different between the groups, neither at baseline nor at the end of study (p > 0.05). Likewise, the groups were comparable regarding MCV, MCH, MCHC, iron, ferritin, TIBC, creatinine, BUN and electrolytes at baseline as well as at the end of trial. Adverse events were not serious and occurred with the same frequency in the study groups. Conclusion: Pastopoitin showed comparable efficacy and safety profile with Eprex in anemic patients on hemodialysis. Hence, Pastopoitin may be considered as a rHuEPO with a lower cost and wider availability compared with the innovator product Eprex.